The SightGlass DOT 0.2 lens presents a new theory in myopia control, with clinical trial evidence of efficacy in children from 6 to 10 years of age. Diffusion Optics Technology (DOT) incorporates microdots to modulate retinal contrast; it does not employ defocus as for other optical treatments. Learn more here.
The contrast theory in myopia development and control is based on links between retinal cone expressions, genetics and myopia. This is distinct from peripheral defocus and simultaneous defocus theories and underpins the new SightGlass DOT 0.2 spectacle lens for myopia control. Learn more here.
Dr Carolyn Lederman, ophthalmologist from the United States, explains how she prescribes and manages myopia patients with the NaturalVue Multifocal 1 Day contact lens in her practice.
A dose-response is where an increasing amount of a medication or intervention is correlated with a better clinical outcome. When it comes to myopia control, we investigate the evidence for a dose-response with spectacle, contact lens, atropine and outdoor time interventions.
This retrospective cohort analysis showed that NaturalVue Multifocal 1 Day contact lens wear appears to result in a mean refractive myopia progression of less than 0.25D per year, based on available data. Some limited axial length data was also presented.
In this case, a colleague has his first experience with the new Essilor Stellest spectacle lens for childhood myopia, with discussion including when to change the prescription and when to stop treatment.
Spectacle lenses which effectively control myopia progression are the next phase in widespread uptake of myopia management. Learn more about the Essilor Stellest lens, from myopia control to vision and visual function outcomes.
Two prototype myopia control soft contact lens designs with non-coaxial optics showed enhanced efficacy in one design and enhanced vision in the other, compared to dual-focus and single-vision designs. This initial data is for six months, and all myopia control contact lens designs showed close to 6/6 or 20/20 acuity equivalent.
Analysis of the BLINK study results showed a global more than localized impact on slowing eye growth in +2.50 CD multifocal contact lens wear. The slowed growth effects were greater centrally than peripherally. This suggests local defocus responses may not provide the full story behind myopia control mechanisms.
In this case, we meet a child whose axial length has progressed 0.4mm in one year, even with myopia control treatment. Yet, his refractive error hasn’t changed. What could cause this and what is the best course of action?
